INTERPLAY BETWEEN CARDIOVASCULAR DISEASE AND CANCER: MECHANISTIC INSIGHTS AND CLINICAL IMPLICATIONS

Abstract

Cardiovascular disease (CVD) and cancer remain the foremost global health challenges, and emerging evidence suggests that their interplay is mediated by overlapping biological pathways and clinical determinants. In this study, we employed a mixed-methods experimental design integrating quantitative analyses from large patient datasets with qualitative thematic insights from cardio-oncology specialists. The results demonstrated that inflammatory biomarkers, including IL-6 and C-reactive protein, were significantly elevated in patients with comorbid conditions, while regression models revealed strong associations between clonal hematopoiesis mutations (DNMT3A, TET2) and dual disease risk. Survival analysis indicated that cancer patients exposed to cardiotoxic therapies exhibited a markedly higher incidence of adverse cardiovascular outcomes, yet the use of statins and beta-blockers was associated with improved survival probabilities across cohorts. Imaging and molecular profiling further highlighted subclinical cardiotoxicity and metabolic reprogramming as convergent hallmarks of disease interaction. Importantly, qualitative data triangulated these findings, with clinicians emphasizing unmet needs in risk stratification, biomarker-guided surveillance, and patient quality-of-life management. The integration of statistical modeling, biomarker assays, and clinician perspectives provides a comprehensive view of how shared pathophysiology translates into tangible clinical outcomes. Collectively, the study underscores that CVD and cancer represent interconnected syndromes rather than independent entities and that early, integrated, multidisciplinary management is essential to reduce morbidity and mortality. These insights establish a translational foundation for advancing precision medicine approaches in cardio-oncology.